JP2020534360A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020534360A5 JP2020534360A5 JP2020537292A JP2020537292A JP2020534360A5 JP 2020534360 A5 JP2020534360 A5 JP 2020534360A5 JP 2020537292 A JP2020537292 A JP 2020537292A JP 2020537292 A JP2020537292 A JP 2020537292A JP 2020534360 A5 JP2020534360 A5 JP 2020534360A5
- Authority
- JP
- Japan
- Prior art keywords
- methylquinoline
- cyclopropane
- carboxamide
- sulfonyl
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021156375A JP7064073B2 (ja) | 2017-09-14 | 2021-09-27 | 嚢胞性線維症膜貫通コンダクタンス調節因子タンパク質のモジュレーター及び使用の方法 |
| JP2021156376A JP7064074B2 (ja) | 2017-09-14 | 2021-09-27 | 嚢胞性線維症膜貫通コンダクタンス調節因子タンパク質のモジュレーター及び使用の方法 |
| JP2022007648A JP2022062093A (ja) | 2017-09-14 | 2022-01-21 | 嚢胞性線維症膜貫通コンダクタンス調節因子タンパク質のモジュレーター及び使用の方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762558430P | 2017-09-14 | 2017-09-14 | |
| US62/558,430 | 2017-09-14 | ||
| US201762608846P | 2017-12-21 | 2017-12-21 | |
| US62/608,846 | 2017-12-21 | ||
| PCT/IB2018/057020 WO2019053634A1 (en) | 2017-09-14 | 2018-09-13 | MODULATORS OF THE TRANSMEMBRANE CONDUCTANCE REGULATORY PROTEIN OF CYSTIC FIBROSIS AND METHODS OF USE |
Related Child Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021156375A Division JP7064073B2 (ja) | 2017-09-14 | 2021-09-27 | 嚢胞性線維症膜貫通コンダクタンス調節因子タンパク質のモジュレーター及び使用の方法 |
| JP2021156376A Division JP7064074B2 (ja) | 2017-09-14 | 2021-09-27 | 嚢胞性線維症膜貫通コンダクタンス調節因子タンパク質のモジュレーター及び使用の方法 |
| JP2022007648A Division JP2022062093A (ja) | 2017-09-14 | 2022-01-21 | 嚢胞性線維症膜貫通コンダクタンス調節因子タンパク質のモジュレーター及び使用の方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020534360A JP2020534360A (ja) | 2020-11-26 |
| JP2020534360A5 true JP2020534360A5 (OSRAM) | 2021-10-21 |
| JP7064072B2 JP7064072B2 (ja) | 2022-05-10 |
Family
ID=63713961
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020537292A Expired - Fee Related JP7064072B2 (ja) | 2017-09-14 | 2018-09-13 | 嚢胞性線維症膜貫通コンダクタンス調節因子タンパク質のモジュレーター及び使用の方法 |
| JP2021156376A Expired - Fee Related JP7064074B2 (ja) | 2017-09-14 | 2021-09-27 | 嚢胞性線維症膜貫通コンダクタンス調節因子タンパク質のモジュレーター及び使用の方法 |
| JP2021156375A Expired - Fee Related JP7064073B2 (ja) | 2017-09-14 | 2021-09-27 | 嚢胞性線維症膜貫通コンダクタンス調節因子タンパク質のモジュレーター及び使用の方法 |
| JP2022007648A Pending JP2022062093A (ja) | 2017-09-14 | 2022-01-21 | 嚢胞性線維症膜貫通コンダクタンス調節因子タンパク質のモジュレーター及び使用の方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021156376A Expired - Fee Related JP7064074B2 (ja) | 2017-09-14 | 2021-09-27 | 嚢胞性線維症膜貫通コンダクタンス調節因子タンパク質のモジュレーター及び使用の方法 |
| JP2021156375A Expired - Fee Related JP7064073B2 (ja) | 2017-09-14 | 2021-09-27 | 嚢胞性線維症膜貫通コンダクタンス調節因子タンパク質のモジュレーター及び使用の方法 |
| JP2022007648A Pending JP2022062093A (ja) | 2017-09-14 | 2022-01-21 | 嚢胞性線維症膜貫通コンダクタンス調節因子タンパク質のモジュレーター及び使用の方法 |
Country Status (34)
| Country | Link |
|---|---|
| US (6) | US10988454B2 (OSRAM) |
| EP (4) | EP3736267B1 (OSRAM) |
| JP (4) | JP7064072B2 (OSRAM) |
| KR (1) | KR20200086661A (OSRAM) |
| CN (1) | CN111954664A (OSRAM) |
| AU (1) | AU2018332512A1 (OSRAM) |
| BR (1) | BR112020005102A2 (OSRAM) |
| CA (1) | CA3074945A1 (OSRAM) |
| CL (1) | CL2020000664A1 (OSRAM) |
| CO (1) | CO2020004249A2 (OSRAM) |
| CR (1) | CR20200157A (OSRAM) |
| CY (3) | CY1123761T1 (OSRAM) |
| DK (3) | DK3681864T3 (OSRAM) |
| EC (1) | ECSP20021913A (OSRAM) |
| ES (3) | ES2856751T3 (OSRAM) |
| HR (3) | HRP20210099T1 (OSRAM) |
| HU (3) | HUE055050T2 (OSRAM) |
| IL (1) | IL273163A (OSRAM) |
| LT (3) | LT3681864T (OSRAM) |
| MA (1) | MA50240B1 (OSRAM) |
| MD (3) | MD3736270T2 (OSRAM) |
| MX (1) | MX2020002806A (OSRAM) |
| PE (1) | PE20210140A1 (OSRAM) |
| PH (1) | PH12020500509A1 (OSRAM) |
| PL (3) | PL3736267T3 (OSRAM) |
| PT (3) | PT3736267T (OSRAM) |
| RS (3) | RS62185B1 (OSRAM) |
| RU (1) | RU2020113350A (OSRAM) |
| SG (1) | SG11202002101RA (OSRAM) |
| SI (3) | SI3736270T1 (OSRAM) |
| SM (3) | SMT202100140T1 (OSRAM) |
| UA (1) | UA125541C2 (OSRAM) |
| WO (1) | WO2019053634A1 (OSRAM) |
| ZA (1) | ZA202002363B (OSRAM) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS60906B1 (sr) | 2014-10-06 | 2020-11-30 | Vertex Pharma | Modulatori regulatora transmembranske provodljivosti za cističnu fibrozu |
| LT3519401T (lt) | 2016-09-30 | 2021-11-25 | Vertex Pharmaceuticals Incorporated | Cistinės fibrozės transmembraninio laidumo reguliavimo moduliatorius, farmacinės kompozicijos, gydymo būdai ir moduliatoriaus gamybos būdas |
| PT3551622T (pt) | 2016-12-09 | 2020-11-12 | Vertex Pharma | Modulador do regulador da condutância transmembrana da fibrose quística, composições farmacêuticas, métodos de tratamento e processo de fabrico do modulador |
| US11253509B2 (en) | 2017-06-08 | 2022-02-22 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| WO2019018395A1 (en) | 2017-07-17 | 2019-01-24 | Vertex Pharmaceuticals Incorporated | METHODS OF TREATING CYSTIC FIBROSIS |
| TWI799435B (zh) | 2017-08-02 | 2023-04-21 | 美商維泰克斯製藥公司 | 製備化合物之製程 |
| US10988454B2 (en) * | 2017-09-14 | 2021-04-27 | Abbvie Overseas S.À.R.L. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
| AU2018350980C1 (en) | 2017-10-18 | 2024-12-12 | Incyte Corporation | Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-y gamma inhibitors |
| US10654829B2 (en) | 2017-10-19 | 2020-05-19 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of CFTR modulators |
| CA3085006A1 (en) | 2017-12-08 | 2019-06-13 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| CA3088577A1 (en) | 2018-02-15 | 2019-08-22 | Vertex Pharmaceuticals Incorporated | Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them |
| US11414439B2 (en) | 2018-04-13 | 2022-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| CR20250050A (es) | 2018-09-05 | 2025-03-19 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165) |
| JP2022514253A (ja) * | 2018-12-18 | 2022-02-10 | ノバルティス アーゲー | Ｎ－（ピリジン－２－イルスルホニル）シクロプロパンカルボキサミド誘導体及びｃｆｔｒ媒介疾患の処置におけるその使用 |
| TWI848092B (zh) | 2019-04-03 | 2024-07-11 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白調節劑 |
| TWI899097B (zh) | 2019-08-14 | 2025-10-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
| TWI867024B (zh) | 2019-08-14 | 2024-12-21 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| US11873300B2 (en) | 2019-08-14 | 2024-01-16 | Vertex Pharmaceuticals Incorporated | Crystalline forms of CFTR modulators |
| WO2022036060A1 (en) | 2020-08-13 | 2022-02-17 | Vertex Pharmaceuticals Incorporated | Crystalline forms of cftr modulators |
| US12612416B2 (en) | 2020-10-07 | 2026-04-28 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| IL303519A (en) | 2020-12-10 | 2023-08-01 | Vertex Pharma | Cystic fibrosis treatment methods |
| EP4274828A1 (en) * | 2021-01-06 | 2023-11-15 | AbbVie Global Enterprises Ltd. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
| WO2022150173A1 (en) * | 2021-01-06 | 2022-07-14 | AbbVie Global Enterprises Ltd. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
| CN116217392A (zh) * | 2023-02-21 | 2023-06-06 | 厦门医学院 | 一种洛索洛芬钠关键中间体2-(4-卤甲基苯基)丙酸酯的合成方法 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB602426A (en) * | 1945-10-24 | 1948-05-26 | Geigy Ag J R | Manufacture of aromatic acyl-sulphonamides |
| JP2004529855A (ja) * | 2000-10-10 | 2004-09-30 | スミスクライン ビーチャム コーポレーション | 置換インドール類、そのような置換インドール類を含む医薬組成物及びＰＰＡＲ−γ結合剤としてのそれらの使用 |
| WO2005120497A2 (en) | 2004-06-04 | 2005-12-22 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-cftr and uses thereof |
| CN101891680B (zh) | 2004-06-24 | 2014-10-29 | 沃泰克斯药物股份有限公司 | Atp-结合弹夹转运蛋白的调控剂 |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| NZ576642A (en) | 2006-11-03 | 2011-11-25 | Vertex Pharma | Azaindole derivatives as cftr modulators |
| AU2008256717B2 (en) | 2007-05-25 | 2013-11-21 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP2197842B1 (en) * | 2007-08-29 | 2012-05-23 | Schering Corporation | 2, 3-substituted indole derivatives for treating viral infections |
| CA2705586A1 (en) * | 2007-11-16 | 2009-05-22 | Schering Corporation | 3-heterocyclic substituted indole derivatives and methods of use thereof |
| EA017919B1 (ru) | 2007-12-10 | 2013-04-30 | Новартис Аг | Производные пиразин-2-карбоксамида для лечения заболеваний, которые поддаются лечению путем блокирования эпителиальных натриевых каналов |
| WO2009076593A1 (en) | 2007-12-13 | 2009-06-18 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| JP2011517674A (ja) * | 2008-03-25 | 2011-06-16 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 嚢胞性線維症膜コンダクタンス制御因子の水溶性小分子阻害剤 |
| EP2358680B1 (en) | 2008-10-23 | 2013-03-20 | Vertex Pharmaceuticals Incorporated | Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide |
| DK2365972T3 (en) * | 2008-11-06 | 2015-01-19 | Vertex Pharma | Modulators of atp-binding cassette conveyors |
| EP2382197B1 (en) | 2008-12-30 | 2016-10-05 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP2421368A4 (en) * | 2009-04-20 | 2013-01-09 | Inst Oneworld Health | COMPOUNDS, COMPOSITIONS AND METHODS FOR PYRIDAZINE SULFONAMIDE DERIVATIVES |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| WO2012048181A1 (en) | 2010-10-08 | 2012-04-12 | N30 Pharmaceuticals, Llc | Novel substituted quinoline compounds as s-nitrosoglutathione reductase inhibitors |
| WO2013038386A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Heterocyclic compounds for the treatment of cystic fibrosis |
| WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| ES2882807T3 (es) | 2011-09-16 | 2021-12-02 | Novartis Ag | Heterociclil carboxamidas N-sustituidas |
| WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
| WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| PT2760463T (pt) | 2011-09-20 | 2019-02-27 | Univ North Carolina Chapel Hill | Regulação de canais de sódio por proteínas plunc |
| MX368263B (es) | 2013-05-07 | 2019-09-26 | Galapagos Nv | Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de fibrosis quistica. |
| JP6425724B2 (ja) | 2013-08-08 | 2018-11-21 | ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． | Ｃｆｔｒモジュレーターとしてのチエノ［２，３−ｃ］ピラン |
| CN103484818A (zh) | 2013-09-25 | 2014-01-01 | 京东方科技集团股份有限公司 | 蒸镀方法、蒸镀装置和发光器件 |
| AU2015229188A1 (en) | 2014-03-13 | 2016-09-29 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing CFTR activity |
| CA2942387A1 (en) | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions and methods of increasing cftr actvity |
| KR102132215B1 (ko) | 2014-04-03 | 2020-07-09 | 삼성전자주식회사 | 자기 터널 접합 구조물 형성 방법 및 이를 이용한 자기 메모리 소자의 제조 방법 |
| RS60906B1 (sr) * | 2014-10-06 | 2020-11-30 | Vertex Pharma | Modulatori regulatora transmembranske provodljivosti za cističnu fibrozu |
| SG10201803472QA (en) * | 2014-10-31 | 2018-06-28 | Abbvie Sarl | Substituted chromanes and method of use |
| US9567322B2 (en) | 2014-10-31 | 2017-02-14 | Abbvie S.Á.R.L. | Substituted tetrahydropyrans and method of use |
| KR20180029204A (ko) | 2015-06-02 | 2018-03-20 | 애브비 에스.에이.알.엘. | 치환된 피리딘 및 사용 방법 |
| US9840513B2 (en) | 2015-07-16 | 2017-12-12 | Abbvie S.Á.R.L. | Substituted tricyclics and method of use |
| PL3359541T3 (pl) | 2015-10-09 | 2021-01-11 | AbbVie Overseas S.à r.l. | N-SULFONYLOWANE PIRAZOLO[3,4-b]PIRYDYNO-6-KARBOKSAMIDY I SPOSÓB ZASTOSOWANIA |
| AU2017256172A1 (en) | 2016-04-26 | 2018-09-06 | AbbVie S.à.r.l. | Modulators of cystic fibrosis transmembrane conductance regulator protein |
| US10138227B2 (en) | 2016-06-03 | 2018-11-27 | Abbvie S.Á.R.L. | Heteroaryl substituted pyridines and methods of use |
| US10399940B2 (en) | 2016-10-07 | 2019-09-03 | Abbvie S.Á.R.L. | Substituted pyrrolidines and methods of use |
| US9981910B2 (en) | 2016-10-07 | 2018-05-29 | Abbvie S.Á.R.L. | Substituted pyrrolidines and methods of use |
| US10988454B2 (en) * | 2017-09-14 | 2021-04-27 | Abbvie Overseas S.À.R.L. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
-
2018
- 2018-09-12 US US16/129,458 patent/US10988454B2/en active Active
- 2018-09-13 EP EP20183405.8A patent/EP3736267B1/en active Active
- 2018-09-13 PL PL20183405T patent/PL3736267T3/pl unknown
- 2018-09-13 LT LTEP18779798.0T patent/LT3681864T/lt unknown
- 2018-09-13 PT PT201834058T patent/PT3736267T/pt unknown
- 2018-09-13 MD MDE20201159T patent/MD3736270T2/ro not_active IP Right Cessation
- 2018-09-13 DK DK18779798.0T patent/DK3681864T3/da active
- 2018-09-13 EP EP21164249.1A patent/EP3865474A1/en not_active Withdrawn
- 2018-09-13 DK DK20183405.8T patent/DK3736267T3/da active
- 2018-09-13 ES ES18779798T patent/ES2856751T3/es active Active
- 2018-09-13 PT PT201834025T patent/PT3736270T/pt unknown
- 2018-09-13 ES ES20183405T patent/ES2887449T3/es active Active
- 2018-09-13 LT LTEP20183402.5T patent/LT3736270T/lt unknown
- 2018-09-13 WO PCT/IB2018/057020 patent/WO2019053634A1/en not_active Ceased
- 2018-09-13 CR CR20200157A patent/CR20200157A/es unknown
- 2018-09-13 PE PE2020000670A patent/PE20210140A1/es unknown
- 2018-09-13 EP EP20183402.5A patent/EP3736270B1/en active Active
- 2018-09-13 MA MA50240A patent/MA50240B1/fr unknown
- 2018-09-13 RS RS20210973A patent/RS62185B1/sr unknown
- 2018-09-13 SM SM20210140T patent/SMT202100140T1/it unknown
- 2018-09-13 HU HUE20183405A patent/HUE055050T2/hu unknown
- 2018-09-13 MD MDE20201160T patent/MD3736267T2/ro not_active IP Right Cessation
- 2018-09-13 KR KR1020207010867A patent/KR20200086661A/ko not_active Abandoned
- 2018-09-13 BR BR112020005102-0A patent/BR112020005102A2/pt not_active Application Discontinuation
- 2018-09-13 PL PL20183402T patent/PL3736270T3/pl unknown
- 2018-09-13 MD MDE20200741T patent/MD3681864T2/ro not_active IP Right Cessation
- 2018-09-13 CA CA3074945A patent/CA3074945A1/en not_active Abandoned
- 2018-09-13 RU RU2020113350A patent/RU2020113350A/ru unknown
- 2018-09-13 SM SM20210493T patent/SMT202100493T1/it unknown
- 2018-09-13 MX MX2020002806A patent/MX2020002806A/es unknown
- 2018-09-13 ES ES20183402T patent/ES2881881T3/es active Active
- 2018-09-13 SM SM20210556T patent/SMT202100556T1/it unknown
- 2018-09-13 SI SI201830345T patent/SI3736270T1/sl unknown
- 2018-09-13 SI SI201830193T patent/SI3681864T1/sl unknown
- 2018-09-13 EP EP18779798.0A patent/EP3681864B1/en active Active
- 2018-09-13 RS RS20210082A patent/RS61899B1/sr unknown
- 2018-09-13 SG SG11202002101RA patent/SG11202002101RA/en unknown
- 2018-09-13 HU HUE18779798A patent/HUE052873T2/hu unknown
- 2018-09-13 LT LTEP20183405.8T patent/LT3736267T/lt unknown
- 2018-09-13 JP JP2020537292A patent/JP7064072B2/ja not_active Expired - Fee Related
- 2018-09-13 UA UAA202002356A patent/UA125541C2/uk unknown
- 2018-09-13 HU HUE20183402A patent/HUE055241T2/hu unknown
- 2018-09-13 SI SI201830344T patent/SI3736267T1/sl unknown
- 2018-09-13 AU AU2018332512A patent/AU2018332512A1/en not_active Abandoned
- 2018-09-13 HR HRP20210099TT patent/HRP20210099T1/hr unknown
- 2018-09-13 RS RS20210975A patent/RS62190B1/sr unknown
- 2018-09-13 CN CN201880073855.3A patent/CN111954664A/zh active Pending
- 2018-09-13 PT PT187797980T patent/PT3681864T/pt unknown
- 2018-09-13 DK DK20183402.5T patent/DK3736270T3/da active
- 2018-09-13 PL PL18779798T patent/PL3681864T4/pl unknown
-
2020
- 2020-03-09 IL IL273163A patent/IL273163A/en unknown
- 2020-03-12 PH PH12020500509A patent/PH12020500509A1/en unknown
- 2020-03-13 CL CL2020000664A patent/CL2020000664A1/es unknown
- 2020-04-07 CO CONC2020/0004249A patent/CO2020004249A2/es unknown
- 2020-04-14 EC ECSENADI202021913A patent/ECSP20021913A/es unknown
- 2020-05-04 ZA ZA2020/02363A patent/ZA202002363B/en unknown
- 2020-05-19 US US16/878,468 patent/US10981890B2/en active Active
- 2020-05-19 US US16/878,421 patent/US10844042B2/en active Active
- 2020-05-19 US US16/878,430 patent/US10829473B2/en active Active
- 2020-05-19 US US16/878,416 patent/US10844041B2/en active Active
-
2021
- 2021-01-28 CY CY20211100074T patent/CY1123761T1/el unknown
- 2021-04-15 US US17/231,482 patent/US20210238159A1/en not_active Abandoned
- 2021-07-26 HR HRP20211200TT patent/HRP20211200T1/hr unknown
- 2021-07-26 HR HRP20211198TT patent/HRP20211198T1/hr unknown
- 2021-08-03 CY CY20211100695T patent/CY1124615T1/el unknown
- 2021-08-04 CY CY20211100697T patent/CY1124401T1/el unknown
- 2021-09-27 JP JP2021156376A patent/JP7064074B2/ja not_active Expired - Fee Related
- 2021-09-27 JP JP2021156375A patent/JP7064073B2/ja not_active Expired - Fee Related
-
2022
- 2022-01-21 JP JP2022007648A patent/JP2022062093A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211198T1 (hr) | Modulatori proteina regulatora transmembranske vodljivosti kod cistične fibroze i postupci upotrebe | |
| JP2017537066A5 (OSRAM) | ||
| JP2016515522A5 (OSRAM) | ||
| JP2016034978A5 (OSRAM) | ||
| JP2015525757A5 (OSRAM) | ||
| WO2017087608A8 (en) | Modulators of ror-gamma | |
| JP2012143233A5 (OSRAM) | ||
| CY1115556T1 (el) | Φαρμακευτικη συνθεση για χορηγηση απο το στομα η οποια περιλαμβανει ετεξιλικη δαβιγατρανη | |
| EA201100358A1 (ru) | Дабигатран для чрескожной хирургической катетеризации сердца | |
| EA201300990A1 (ru) | Парентеральное введение тапентадола | |
| JP2018519259A5 (OSRAM) | ||
| UA112556C2 (uk) | Інсектицидні похідні 2-метоксибензамідів | |
| RU2017145271A (ru) | Терапевтическое средство для фиброза | |
| MX363389B (es) | Composicion farmaceutica que comprende ivabradina amorfa. | |
| JP2017513944A5 (OSRAM) | ||
| EA201991286A1 (ru) | Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин | |
| AR108233A1 (es) | Composiciones farmacéuticas orales de nicotinamida | |
| MX356789B (es) | Composición de difenidol de liberación prolongada. | |
| JP2017014205A5 (OSRAM) | ||
| JP2015509917A5 (OSRAM) | ||
| CN105764509A (zh) | 达比加群酯或其盐的投药制剂及其制备方法 | |
| JP2014526458A5 (OSRAM) | ||
| JP2021534316A5 (OSRAM) | ||
| CN302322174S (zh) | 超声波焊头（z系统） | |
| WO2019004979A3 (en) | SOLID ORAL PHARMACEUTICAL COMPOSITIONS OF DABIGATRAN DEXILATE |